ObJective: To determine national pediatric prescribing practices for psychotropic agents and to examine these practices in view of the available evidence concerning their safety and efficacy In this age group. Method: Prescribing data from 2 national databases baaed on surveys 01 olfice-based medical practices were determined and reviewed vis-ii-vis available safety and efficacy evidence. Results: Data indicate that levels of psychotropic prescribing In children and adolescents are greatest for stimulants, resulting in nearly 2 million office \/lslls and 6 million drug "mentions· In 1995. Selective serotonin reuptake inhibitors were the second most prescribed psychotropic agents, while anticonvulsant mood stabilizera (prescribed for a psychiatric reason), tricyclic antidepressants, central adrenergic a9Onlsts, antipsychotics, benzodlazeplnes, and lithium were also prescribed for a substantial number of office visits. Comparison of prescribing frequencies with available safety and efficacy data Indicates significant gaps In knowledge for commonly used agents. Conclusions: Most psychotropic agents reqUire further sustained study to ensure appropriate health care expenditures and vouchsafe children's safety. Recommendations for researchers, parents, federal agencies, and indUstry are offered as a means to accelerale the pace of reseerch progress. J. Am. Acad. Child Ado/esc. Psychiatry. 1999.38(5):557-565.
evidence of safety and efficacy. The possibility of substantial prescribing rates of psychotropic medications for children and adolescents and the lack of data on their effects (adverse or beneficial) in children is troubling because response to psychotropics in youth may be altered by developmental factors that may modify drug response (biological variability. pharmacodynamics. and pharmacokinetics) and other potential vulnerabilities in children (Vitiello and Jensen, 1995) .
Media reports of increasing exposure of children to psychotropics highlight the concerns regarding the gap between what is known about these agents and how they are actually used. Remarkably, these same concerns apply not just to psychotropics but to all medications used in children: thus, 80% of all medication use in children is estimated to be: "off-label" (American Academy of Pediatrics Committee on Drugs, 1996) .
To date, studies of rates of pediatric psychopharmacological prescribing have largely been confined to geographically circumscribed swings (reviewed by Gadow. 1993) , institutional or clinic settings (reviewed by Singh et al., 1998) , or national studies of stimulant treatments alone (e.g., Zito et al .• 1997) . Such studies cannot be used to estimate the national rates of overall psychotropic use in the United States and are limited by their nonrepresentative nature (Kaplan and Busner, 1998; Kaplan et al.. 1994; Safer. 1998; Zito et al.. 1994) .
Our review of the literature revealed that 2 studies have examined national data concerning psychotropic prescribing patterns in youth. Kelleher et al. (989) used the 1985 National Ambulatory Medical Care Survey (NAMCS) to estimate national psychotropic use in patients younger than 18 years of age. They found that 1.5% of all office visits involved prescription of a psychotropic. Stimulants were, by far. the most frequently prescribed psychotropic medication. Prescription rates per pediatric office visit for psychotropic agents of all types were highest for psychiatrists by many orders of magnitude. followed by family physicians, pediatricians, and internists. (The absolute order among the nonpsychiatrist specialties varied somewhat. depending on the psychotropic agent). Because of the evidence for substantially increased pediatric prescribing in recent years (Safer et aI., 1996) , this study cannot be used to inform knowledge of current rates of pediatric psychotropic medication prescribing.
More recently, Safer and associates (996) examined time-trend findings from several regional and national databases (2 large population-based databases, 3 pharmaceutical databases. and 1 physician audit) to estimate the prevalence of methylphenidate treatment in youth with attention-deficit hyperactivity disorder (ADHD) during the 1990s. They estimated that the number of U.S. children aged 5 to 18 receiving methylphenidate was 1.5 million in 1995. Of note, however, their repoft was restricted to methylphenidate only.
To address the gaps in our knowledge concerning current psychotropic medication prescribing practices for children and adolescents, we repon below prescribing rate dara drawing from 2 national surveys of office-based medical practices: the NAMCS and the National Disease and Therapeutic Index (NDTI). NAMCS is a large, national probability sample survey of patient visits to office-based practices, conducted annually by the Narional Center for Health Statistics. NAMCS is structured to collect data on office visits only. Prescription rates provided by NAMCS are not directly equivalent ro the frequency of drug use per patient: because the unit of analysis is "visits" rather than patients. prescribing rates can be generalized to the frequency of medication prescription per office visit 558 only. NDTI is a pharmaceutical marketing database available from IMS America Inc. (IMS America. 1995) . In contrast to NAMCS. physicians in the NDTI survey report on all patient contacts (office or hospital; face-toface or by phone). NDTI uses the term "mentions" to denote the times a drug is prescribed. refilled. recommended. or given to a patient as a sample.
Our analyses were conducted on NAMCS and NDT! data for the year 1995, specifically focusing on visits by children younger than 18 years to physicians for psychiatric reasons that also involved prescribing of a psychotropic medication.
METHOD

NAMeS
A delailed drscriplion of lhe survey design, dala colleclion procedures. and lhr estimalion process is provided by Schapprn (1994) . Thr 1995 NAMCS had a mullislage drsign. involving probabilil)' samplrs of primary sampling unils. mrdical practices within primary sampling unils, and palirnl visilS wilhin practices. For lhr 1995 survey. lhr dala wrrr oblainrd from a 10lal of .%.875 palirnt record forms, provided by a nalional samplr of 1.883 office-based physicians who panicipatrd in lhe survry (Nalional Cenler for Health Slalislics, 1997) . The basic sampling unit was a paliem visil 10 physicians rngaged in office-basrd palirm carr and who wrrr lisled in ma5lrr filrs maimainrd by lhr American Medical Associalion lAMA) and the American OSleopalhic Associalion (ADA). AneslhesiologiSlS, palhologists, radiologisls, and federally cmployrd physicians wrre excluded. The physician universe. so defined. was composed of .~7S.4(,7 physicians in 1995. Thc l'J'JS NAMeS "'Imple included 3.724 physicians. Howcvrr. I.B7 physicians were excluded because lhey were relired or rmployed in traching. research. or adminislralion. Of [he remaining 2,587 physicians, 73% (1.883) panicipaled in the sludy.
Each record in lhe NAMCS dala file rrpresenls 1 visit from lhe 10lal sample of .%.875 visilS. Thrse dala were weigh led by an inAalion faclOr ("lhr palirm visil weigh!") on lhe 36.875 rccords. 10 produce nalional eslimales of lhe annual frcqurncirs of medicalion use and ulilizalion of ambulalory mrdical care services. Calculations of annual visil ralrs wrrr basrd on estimales of lhe populalion as of July 1. 1995, oblained from lhe U.S. Bureau of Census. An estimaled 100ai of 697,082.010 office visils madr in lhr Uniled Slales was obtained by lhis melhod. Physicians colleclrd dala by using 2 forms: the Patirm Log and the Palienl Record. I'aliem Logs sequentially lisled palienls seen in lhe offices during lhr assignrd reponing week•. During rach visil. Palirnl Record forms were used 10 coUrcl informalion on ptrSCriplions and a limilrd numbrr of paliem variablrs (age. srx. rrason for visil.ICD-9 diagnoses. and concom ilam drugs).
NOTI
The 1995 N OTI was slruclUred 10 collect dam on palleens and tlcalment of disease in U.S. officr-basrd medical praclicrs. A 2-s1age malified, c1uslered. randomly drawn sampling design involving a prrcision estimalion methudology was used. Thr basic sampling unil was rhe physician workday. Physicians collecled dala on all palienr comacrs during 2 consecutive workdays every 3 momhs. The assignmen! of reponing days to physicians was randomized 10 ensure coverage of each workday. The physician universe consisled of specialties Ihal primarily diagnose and lreat disease (e.g.• palhology and ancslhesiology were excluded). For the 1995 survey. Ihe sampling universe consisted of 333.621 physicians (lMS America. 1995 
MEDICATION PRESCRIBING PRACTICES
RESULTS
The estimated frequencies of the 11 groups of psychotropies are displayed in descending order in Tables 1  and 2. Table 1 displays the NAMes data on the number of visits to office-based medical practices that involved prescription of a psychotropic for a psychiarric reason to yOUlh by physicians of all types (specialist or primary care). This table projects the acrual number of visits to yield national estimates of pediatric visits for psychotropies during 1995. Not surprisingly, the number of office visits resulting in a psychotropic prescription was the highest for stimulants, prescribed in nearly 2 million visits. SSRls were the second most prescribed psychotropic. and the number of office visits associated with SSRI prescription was greater than those involving TeA prescriptions. Lithium and anticonvulsant mood stabili7..ers (valproate and carbamazepine prescribed for a psychiatric reason), central adrenergic agonists (c1onidine and guanfacine), antipsychotics, and benzodiazepines were also prescribed during a substanrial number of office visits. However. the number of visits for the remaining categories of psychotropics was too small for a reliable computation. For example. projection of n for non-SSRI, non-TCA antidepressants (trazodone. nefazodone. and venlafaxine) to the national estimates resulted in a 95% confidence interval of 0 to 33.690, indicating unreliability. The 1995 NOTl dara on the pediarric use of psychorropics are summariz~d in Table 2 . which shows number of psychotropic mentions for a psychiarric reason by all types of office-ba.~ed physicians. The greatest number of drug mentions occurred in rhe stimulant category, nearly 6 million during 1995. The number of mentions for SSRls was about 1.08 million and that for TCAs was 0.97 million. Other noreworrhy mentions included central adrenergic agonists, lithium, anticonvulsant mood stabilizers, ancipsychotics, and benzodiazepines, but the ns were smaller for these categories.
DISCUSSION
To our knowledge, this is the first study to document the extent of pediatric use of all types of psychorropics in the United States during the 19905. Data from both surveys revealed mat stimulants are the most frequently prescribed psychotropic agent in the United States during 1995. followed by th~SSRIs. The concordance of results between NAMCS "visits" and the NOTl "mentions" lends greater credence and interpretability to our findings. Because NAMeS data are restricred to office visits and NOTI mentions are more inclusive of all types of physician-patient contacts. rates of NOTl psychotropic "mentions" are expecredly greater than those obtained from NAMCS "visits," generally 2-fold or more.
Examinarion of both databases indicates rhat the SSRIs are used more often than TCAs, suggesting a TCA-to-SSRI shift in youth during the 1990s as SSRls came on the market (Safer, 1998) . A similar shift is already well documented in adults (Olfson and Klerman, 1993) . With the exceprion of stimulants and SSRIs, the ns for the NAMCS database are too small for valid estimates (fewer than 30 records are considered unreliable for this survey). Nonetheless, NAMCS data tentatively suggest that cenrral adrenergic agonists and TCAs were among the 5 most frequently prescribed psychotropics during pediatric office visits in 1995. This suggestion is strengthened by the support from the NOTI data. which found that TCAs were the third most frequently mentioned psychotropics and central adrenergic agonists ranked fourth in the frequency of mentions.
The NOTI data on anticonvulsant mood stabilizers do not correspond with that from NAMCS. Whereas these agents were ranked the fourth most frequently prescribed psychotropic class by NAMCS visits. they were ranked seventh by NOTI mentions. The likely low 560 reliability of the mood stabilizer data was also suggeSlCd by comparisons of visits: mention ratios for commonly prescribed psychotropics. While the visits/mentions ratio is approximately 1:2 to 3 for stimulants. SSRls. TCAs, and central adrenergic agonists. this ratio was reversed in favor of visits for anticonvulsants (1.7: I). Our anticonvulsant use results may have been confounded by difficulties discriminating their use as mood stabilizers versus their use for seizure disorders in one or both databases or by the need for more frequent office visits to monitor blood levels. We took great care to separate anticonvulsant use data for seizure disorders, but errors in physician coding of diagnostic and reasons for visit data cannot be excluded.
The visits/mention ratio for benzodiazc:pines is the lowest of all the ratios. 1: 1.4, perhaps indicating that these medications are rarely prescribed or refilled without a specific office visit for that purpose, or possibly reflecting the unreliability of these estimates for infrequently prescribed medications. Yet taken together. the NAMCS and NOTI data suggest that antipsychotics and benzodiazepines are among the 7 most commonly used psychotropic classes, while other agents such as lithium, bupropion, buspirone. and new antidepressants are among the least prescribed psychotropic agents in children.
Our results should be interpreted with caution because these databases are limited in several ways. It is important to note thar the sample size of children seen for psychiatric reasons was relatively small in both databases. resulting in lower reliability of estimates in youth than in adults (Zito and Safer, 1998) . Reliability may be compromised by other factors as well. Thus. on the basis of comparisons of 1991 stimulant prescription activity from 3 databases. Safer et al. (1996) found that databases generally yic:lded differing estimates of drug prescription rates that varied with the source. While an examinarion of prescribing rate trends within a given database over the period of several years might increase confidence in overall prescribing panerns, space limitations precluded {hese analyses in this teport.
These databases have other limitations as well. Derived estimates do not take into account the uncertain compliance of patients. nor other factors that are likc:ly to affect prescribing practices (e.g.• reliability of physician diagnoses, diagnostic indication, socioeconomic status. payer, etc.) (Olfson et a!.. 1998) . Both databases do not provide information about the duration or dosage of the drug trials or treatment response, nor do they The mechodology of che 2 databases does not allow direcc estimation of the number of children receiving psychocropic agents, thereby making ic difficulc co determine che public health impact of physicians' current prescribing pracciccs. Nonetheless, in the absence of other nacional pediatric psychopharmacoepidemiological data, our results are informacive of national panerns of pediatric psychotropic exposure. Patient-specific prescription and use rates would require confirmation with primary data collection sources directly from a national sample of children, rather than primarily relying on prescribing daca provided by physicians, The implications of these findings for researchers and policymakers can be gleaned by examining our resulcs in terms of current level of prescribing and safety/efficacy knowledge (Table 3) . We divided the dara inco 3 levels (A, B, and C) based on the level of support for cheir use, as suggesccd by the Incernacional Psychopharmacology Algorithm Project (Jobson and Porrer, 1995; Viciello, 1997) . Level A denotes suppon by 2 or more randomized controlled rrials (RCTs), B-leve! data indicare suppon by ar least one RCT, and Cleve! data are based only on informed clinical opinion, case repons, or open, uncontrolled trials. We adapred rhese levels for rhe pediatric population hy assigning level C (Q all adulthased controlled data in the ahsence of appropriate trials in children. Unlike Johson and )lOIter, we also used these levels to inform the safety datahase; thus, the above definitions of levels A, B, and C were retained to depict the short-term safety database. However, because level A (2 or more RCTs) for long-term safety dara may be neither ethical nor feasihle, we relied here on the availability of pharmacoepidemiological evidence of safety with low incidence of adverse event reports to the Food and Drug Administration (FDA). The B-Ievel data in the context of long-term safety implied that clinically significant adverse events were restricted to case repons andlor anecdotal reports. suggesting possible rare side effects, while level C refern:J co no data or minimal data supporting long-term adversity or safety.
These] levels depiC[ our assessment of the currently availahle pediatric safety and efficacy dara for 8 psychotropic groups. sorting groups by level of use. Inspection of Table 3 reveals a significant mismatch between the level of prescribing of nonstimulant psychotropics and thl: scientific knowblgl: regarding their usc.
Safety
For psychotropics to bl: used in pl:diatric populations. a risk-bendlt analysis that includes safety is crucial. The application of existing safcty datahases for most psychotropics to the pediatric population is limited. however. Despite the increasing empha.~is on inclusion of special populations, premarkcting RCTs do not generally include a sufficient number of children or adolescents. Consequently, their results arc nor generalizable to the pediatric populations that may be exposed to the drug after approval.
In addition. limiwlions inherent in RCT methodology diminish irs value in determining safety of psychotropics in YOllth. Fitsl, premarketing RCTs are not typically large enough (II = 3,000-4,000) to detect a rare adverse drug evenr (ADE) even in adults (Lewis. 1981) . Second. the duration of a typical RCT (less than a year) is too short for detection of long-term ADEs or those that have a long tHency period. Third, exclusion of comorbid conditions and concomitant medication decreases the gcneralizability of safety results from RCTs. Finally, RCT~arc usually used for the indications for which the efficacy is beingstudil:d. not for the actual evolving use of the medication. Wirhin RCTs, the clinical condition may be narrowly ddlncd and atypical cases excluded.
562
Given the limitations of the available safety data as well as the companion difficulties entailed in mounting sizable RCTs in children and adolescents. we suggest rhat knowledge of shorr-term safety data in pediatric psychopharmacology be based on evidence from a minimum of 300 youths exposed to the pharmacological agent during controlled clinical trials. However, this will only detect ADEs occurring more frequently than I in 100 exposed youth. and rare but serious ADEs (such as possible desipramine-related cardiac mortality) may be seldom noted (Biederman et al.. 1995) . Thus. RCT data in youth mllst be augmented by long-term pharmacoepidemiological studies in youth as well as experimental data from developing animals (Jensen et aI., 1994; Zito and Riddle. 1995) . Longitudinal pediatric data arc especially needed, because most psychiatric disorders of childhood and adolescence tend to be chronic, frequently requiring long-term pharmacological treatment. In addition, long-term risks associated with psychotropics may be underrecognized, underreported, and understudied. While psyehopharmacoepidemiological data are less rigorous than those from RCTs. such data may be more representative of the general pediatric population, hence more generalizahle (Zito and Riddle. 1995) .
In the absence of long-term safety data for most psychotropics in youth, the unique developmental effects of psychotropics in children and adolescents are not known. Thus. it must be determined whether long-term psychotropic treatments produce sustained improvement and positively impact the course of disorders (e.g.• decreased kindling and reduced behavioral sensitization in bipolar children by mood stabilizers) or whether long-term use causes developmental (particularly neurodevelopmental) toxicity.
To some extent. the nonpsychiatric literature can be a useful. albeit limited source of safety data for psychotropics that are also used for nonpsyeh iatric reasons. For example, carbamazepine (CBZ) is used both as an anticonvulsant and as a mood stabilizer. A review of the pediatric epilepsy literature reveals that CBZ is generally well tolerated over the long-term and its use is associated with few cognitive problems. However, the neurological literature may not address the issues of CBZ-induced mania and possible differential effects of this agent in children with seizures versus those with bipolar disorder. Whereas the epilepsy literature suggests that CBZ use is associated with few behavioral or cognitive side effects (Herranz et a1.. 1988) , thete are at least 4 case reports of CBZ-induced mania in the child psychiatric literature (Bhatara and Carrera. 1994; Myers and Carrera, 1989; Pleak et al.. 1988; Reiss and O'Donnell, 1984) , as well as an open study in persons with mental retardation suggesting that the "pure" psychiatric use of CBZ is more frequently (p < .05) associated with adverse behavioral effects than the use of CBZ as an anticonvulsant (Friedman et aI., 1992) .
Relatedly, rhe authors of a controlled study of CBZ in children with aggressive behavior reported the frequency of side effects was higher with CBZ than with lithium in similar populations (Cueva et aI., 1996) . The possibiliry that CBZ may cause behavioral side effects more frequently in youth with bipolar disorders than those with seizure disorders can only be tested by including data from children and adolescents with bipolar disorders. Such considerations suggest important constraints on the generalizabiliry and excessive reliance on nonpsychiatric parient studies for inferences about pediatric psychiatric popularions.
Specific Gaps in Safety
Data. There appears ro be increasing interest in and usc of the SSRls and novel antipsychotics in the 1990s, as evidenced by the reported TCA-ro-SSRI shift during the 1990s (Safer, 1998) . But because these agents have been introduced only during the past decade, much still needs ro be learned about their safety, particularly the effects of their long-term administration in youth. Long-term safery data for both of these new psychotropic categories in youth arc still sparse, further highlighting the need for systematic efforts ro address these knowledge gaps.
Another major area of deficiency of safery knowledge concerns the increasing use of combined therapies (polypharmacy) in the face of almost no data on drug-drug interactions in children. For example, several fatalities allegedly caused by c1onidine-methylphenidate interactions were reported to the FDA in 1995 (Popper, 1996; Swanson et aI., 1996) . Yet even roday, systematic data on the combined use of clonidine and methylphenidate remain sparse. Similarly. although SSRls arc known ro have potential for several drug-drug interactions in adults, interactions of SSRls with various drugs used in pediatric patients remain poorly studied.
Efficacy
Ideally, not only should the efficacy of psychotropics be supported by a A-level data (>2 RCTs) , but evidence ). AM. ACAIl. CHII.Il AI)(JI.ESC. I'SYCHIATRY . .lK:~. MAY 1')')') MEDICATION I'REsCRlflIN<.; PRACTICEs for the long-term efficacy of agems should also be available. This poim is illustrated by reviewing the research evidence for pediatric use of 2 most frequently used classes: stimulants and SSRls. A-level data are available for short-term efficacy and safery of stimulams. Although the data on long-term efficacy of stimulants are limited, outcomes from 4 longer-term trials are just now becoming available (e.g., Arnold et aI.. 1997; Gillberg et a!" 1997; Hechtman and Abikoff, 1995; Horn et aI., 1991) .
The efficacy of SSRls in depressed youth is supported by one RCT (level B), but the use of SSRls in obsessivecompulsive disorder (OCD) is supported by A-level data. By contrast, there are no controlled data supporting the use of SSRls in pediatric anxiery disorders other than OCD. Thus, additional short-and long-term efficacy data arc needed for SSRIs. because the disorders for which SSRls are used tend to be chronic or recurrent (e.g., depression and anxiery disorders),
Specific Gaps in Efficacy Data.
Given the inadequacy of efficacy data for most nonstimulant psychorropics, studies are needed for the majoriry of agems. However, efficacy data appear to be most urgently needed for SSRls, mood stabilizers, and novel anti psychotics, as the level of use of these psychotropics appears to be highest in the growing list of psychorropics used in youth. In comrast to adult psychopharmacology that is focusing on differential efficacy and speed of onset of these caregories of psychotropics, pediatric psychopharmacology needs basic studies of the efficacy of these agents.
Conclusion
While the pharmaceutical industry is showing increased interest in conducting psychotropic medication trials in children and adolescents, the rate of progress is likely to be slow without sustained federal leadership and support. To address these difficulties. the FDA has made, in recent years, a comprehensive effort to increase the number of new drugs with clinically significant use in pediatrics that carry adequate labeling for pediatric use. In 1994, the FDA requested the pharmaceutical industry to survey the available data on the efficacy and safety of marketed medications in children for the purpose of determining whether those data are sufficient to support additional pediatric usc information in the labeling (FDA, 1994) . More recently, the FDA has proposed new regulations requiring manufacturers that develop new chemical entities for therapeutic indications to submit data relevant to the efficacy and safery of these compounds in pediatric populations (FDA, 1997) . These data will have to be provided before the approval of the drug to enter the market or soon afrer its approval. On a case-by-case basis, these data will nor be required for compounds that are unlikely to be used in children. If approved, these regulations will significantly increase the authority of the FDA to mandate research in children for future drugs. Based on current regulations, the FDA already has the alilhority to require manufacturers of marketed drugs to provide safety and efficacy data in children in certain circumstances.
Several institutes of the National Institutes of Health (NIH) arc also actively addressing the problems of lack of information. Thus, the National Institute of Mental Health and the National Institute of Child Health and Human Development of the NIH have developed pediatric pharmacology research networks, each consisting of 7 or more regional research units focused on safety and efficacy of medications in children. Also, the NIH has recently implemented new guidelines that presume the inclusion of children in all studies of human subjects (including clinical trials),~l the condition or disorder under study is found in children and if there are no overriding ethical, regulatory. or safety issues barring the inclusion of children in the study.
Despite signs of progress, it will be important that industry. NIH institutes, pharmacology investigators. and families work closely together to address these knowledge gaps. We offer several straightforward. though possibly controversial recommendations:
First. whenever possible, practitioners and professional associations should enCOllrage the enrollment of children in responsibly conducted rigorous clinical trials, rather than simply provide the medications in the absence of supporting evidence. This may help address the difficulties in recruiting sufficient subjects for clinical trials, as well as mitigate the ongoing prescriptions of medications that may be neither safe nor effective.
Second, the NIH institutes should strategically target the development of short-term safety and efficacy studies where knowledge gaps are the greatest (e.g.• SSRIs, mood stabilizers), levels of prescribing are the highest (e.g., SSRIs), and/or potential for toxicities with long-term exposure most prominent (e.g., novel antipsychotics, SSRIs).
Third, the FDA should continue its effortS to introduce the recently proposed new regulations mandating pediatric studies for new pharmacological entities and 564 putsue the full implementation of its regulatory authority to encourage the development of clinical trials in children and adolescents. For example, for agents that appear likely to be used in children and adolescents who have psychiatric illnesses comparable with those in adults, rhe pharmaceurical company might be asked to start the necessary pharmacokinetic, dose-ranging, and short-term efficacy studies in pediatric patients before FDA approval is given for the medication indication in adults.
Fourth, for companies that voluntarily develop medications and indications for children and adolescents, extension of patent life may help offset the costs of such studies and the potential liability the company may bear.
Fifth, long-term safety and efficacy will not likely be supported by industry on a voluntary basis; thus, responsible agencies within the federal government (FDA, NIH) should ensure that issues related ro long-term safety and efficacy of psychotropic agents arc systematically examined. The FDA's MedWatch system (Kessler, 1993) , which allows physicians to report adverse events on a voluntary basis. may be insufficient to track fairly common behavioral adverse events that easily may be confused with the manifestations of the psychiatric disorder itself. Thus, more comprehensive assessment and monitoring data are needed, perhaps similar to tumor registries or ongoing efforts in pediatric and family practice research networks.
Finally. longitudinal. naturalistically gathered clinical data alone will be insufficient to fully address the possibility of drug toxicities, particularly behavioral side effects. Thus, experimental data constirute crucial evidence. Strategic studies with animal species may be required to specifically examine the effects of psychotropic agents on brain maturation during critical periods of neurodevelopment.
While simply gathering safety data may seem pedestrian from a narrow scientific perspective, it is a public health imperative, and this responsibility must be shared by NIH, FDA, scientists, and informed consumer groups. The lack of safety and efficacy data for psychotropic medications is of general concern, not just for parenrs of children with mental illness and their physicians, but for all with a stake in the future of the nation's children. These initiatives, if appropriately pursued, should allow us cautious optimism for pediatric psychopharmacology, and more importantly, for the futures of children with mental illness.
